Genmab — September 2019
-
Jeps..nogle af Genmab´s aktionærer´s veje er uransagelige!
-
Det er en heftig oms og kursen bølger frem og tilbage mellem 1355 og 1375. Må ikke håbe det er et skib i havsnød!
-
The study met the primary endpoint of improving progression free survival (PFS). The regimen resulted in a 37% reduction in the risk of progression or death in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with Kd (HR=0.630; 95% CI: 0.464, 0.854; p=0.0014)
-
Sådan!! Solsen.
-
Du er den fødte Genmab-optimist..:-D
-
På en god nyhed kan en storsælger lukrere på, at kursen trods alt ikke falder så meget. Der er jo købere i markedet på nyheden.
-
Hvor skulle nogen storsælge??
-
I det mindste kan vi glæde os over at JP Morgan nu tilskriver den resterende pipeline significant værdi: "Genmab has several assets with the potential to be the next blockbuster
It believes that upcoming clinical news flow catalysts should drive the shares the next 12-18 months.
As the proprietary pipeline starts to mature we see Genmab going back to being a Biotech with the focus shifting towards the pipeline," JPM adds. -
Der bliver byttet aktier i den grad!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind